Description: The aim of this study is to determine whether the addition of novel sodium glucose cotransport-2 inhibitors (SGLT2i) to standard of care leads to reduced intraglomerular pressure and suppression of proteinuria, with a further goal of examining mechanisms of SGLT2 inhibition by measuring renal hemodynamic function and sodium handling
|Condition||-AIDS Associated Nephropathy
|Start Date||April 1994|
|Age||4 years and older|
|Accepts Healthy Volunteers||Yes|
- An unlimited number of subjects with known or suspected glomerular or tubulointerstitial disease will be eligible for study. No sex, race or ethnic selection will be applied.
Frequently Asked Questions (FAQs):
- This study is listed as an observational study. What does that mean?
- An observational study is a study attempting to find a cause-effect relationship. For this study, researchers will attempt to learn more about the pathogenesis of glomerulosclerosis.
- What would I/my child have to do if enrolled in this study?
- Selected subjects will be invited to provide informed consent to undergo a kidney biopsy for research purposes. Blood, urine, and tissue samples will be evaluated both for standard diagnostic purposes and for research purposes.
Who can participate?
Children and adults 4 years or older with known or suspected glomerular or tubulointerstitial disease.
Who do I contact with general questions?
Please call or email Jessica M. Warren at (301) 451-9946 or firstname.lastname@example.org respectively with any questions.
Where can I learn more?
Contact Information by Trial Site
|State||City||Site Name||Contact Information|
|MD||Bethesda||National Institutes of Health Clinical Center||Jessica M. Warren: (301) 451-9946, email@example.com|